Previous 10 | Next 10 |
Genprex CFO Ryan Confer provides a preview of their upcoming presentation at NobleCon18 NobleCon18 - Noble Capital Markets 18th Annual Small and Microcap Investor Conference - April 19-21, 2022 - Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentat...
Genprex (NASDAQ:GNPX) said it was opening patient enrollment for Phase 1/2 trial testing its lead drug candidate, Reqorsa in combination with Merck's Keytruda in patients with late-stage non-small cell lung cancer (NSCLC). The trial , dubbed Acclaim-2, will test the c...
Company Has FDA Fast Track Designation for Combination of REQORSA and Keytruda Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients wit...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its president and CEO Rodney Varner will provide an overview of the company’s gene therapies for cancer and diabet...
Investor presentation to highlight the Company’s gene therapies for cancer and diabetes Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies ...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the first patient was dosed in the Acclaim-1 clinical trial. The open-label, multi-center phase 1/2 clinical trial will e...
Company has FDA Fast Track Designation for combination of REQORSA and Tagrisso Preclinical Data Presented at American Association of Clinical Research (AACR) 2021 Showed That REQORSA Can Overcome Resistance to Tagrisso Genprex, Inc. (“Genprex” o...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating in two investor conferences this month. The company has announced that president and CEO Rodney Varner will be presenting...
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodn...
What’s going on in the stock market today? You probably know that things have been very volatile if you’ve been watching the trading action over the last month. And no class of stocks enjoys volatility quite like penny stocks . There aren’t many places where you can...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...